1. Sandercock, C.G. & Storz, U. Nat. Biotechnol. 30, 615–618 (2012).
2. Biogen Idec., Inc. and Genentech, Inc. v. GlaxoSmithKline., LLC, et al., 713 F.3d 1090 (Fed. Cir. 2013).
3. AbbVie Deutschland GmbH & Co., et al. v. Janssen Biotech, Inc. and Centocor Biologics, LLC, 759 F.3d 1285, 1289–90, 1294 (Fed. Cir. 2014).
4. UCB, Inc., v. Yeda Research and Development Co., Ltd., 2015 WL 4619996 at *1, 117 F.Supp.3d 755 (E.D. Va. July 15, 2015), affirmed, Appeal 2015–1957, (Fed. Cir., Sept. 8, 2016).
5. See, Amgen, Inc. et al. v. Sanofi-Aventis U.S. LLC et al., No. 14–01317-SLR, 2016 slip op. (D. Del. March 16, 2016).